Table 1.
Baseline characteristics of MTOPS cohort.
| Characteristic | Cohort (N=3047) |
Placebo (N=737) |
Doxazosin (N=756) |
Finasteride (N=768) |
Combination (N=786) |
|---|---|---|---|---|---|
| Age, year (range, 50–89) | 62.6 (7.3) | 62.5 (7.6) | 62.7 (7.3) | 62.6 (7.3) | 62.7 (7.1) |
| AUA Symptom Score (range, 8–35) | 16.9 (5.9) | 16.8 (6.0) | 17 (5.9) | 17.1 (6.0) | 16.8 (5.8) |
| Prostate volume, ml (range, 6.1–185.0) | 36.3 (20.1) | 35.2 (18.9) | 36.9 (21.6) | 36.9 (20.6) | 36.4 (19.2) |
| Maximal urinary flow rate, ml/sec (range, 4–15.3) | 10.5 (2.6) | 10.5 (2.7) | 10.3 (2.6) | 10.5 (2.6) | 10.6 (2.5) |
| Post-voiding residual volume, ml (range, 0–789) | 68.1 (82.9) | 69.6 (82.1) | 69.2 (88.3) | 66.2 (80.1) | 67.5 (81.2) |
| Serum PSA, ng/ml (range, 0.2–10.5) | 2.4 (2.1) | 2.3 (2.1) | 2.4 (2.2) | 2.4 (2.1) | 2.3 (2.0) |
| Serum glucose, ng/dl (range, 6–465) | 100.1 (42.5) | 100.8 (43.9) | 99.3 (41.6) | 98.6 (37.4) | 101.6 (46.4) |
| BMI, kg/m2 (range, 16.5–52.1) | 27.8 (4.2) | 27.6 (4.0) | 27.7 (3.9) | 27.9 (4.6) | 27.9 (4.2) |
| BPH Impact Index (range, 0–13) | 4.0 (2.7) | 4.0 (2.7) | 3.9 (2.7) | 4.1 (2.8) | 4.0 (2.7) |
| Primary school education only, n (%) | 120 (3.9) | 29 (3.9) | 36 (4.8) | 31 (4.0) | 24 (3.1) |
| Family history of prostate cancer, n (%) | |||||
| Yes | 416 (13.7) | 95 (12.9) | 94 (12.4) | 98 (12.8) | 129 (16.4) |
| No | 2228 (73.1) | 545 (74.0) | 546 (72.2) | 578 (75.3) | 559 (71.1) |
| Unknown | 403 (13.2) | 97 (13.2) | 116 (15.3) | 92 (12.0) | 98 (12.5) |
| Impotence, n (%) | |||||
| Yes | 747 (24.6) | 185 (25.1) | 196 (26.0) | 184 (24.0) | 182 (23.2) |
| No | 1745 (57.4) | 417 (56.7) | 423 (56.0) | 456 (59.4) | 449 (57.3) |
| Intermittent | 550 (18.1) | 134 (18.2) | 136 (18.0) | 128 (16.7) | 152 (19.4) |
| History of diabetes, n (%) | 260 (8.5) | 72 (9.8) | 59 (7.8) | 65 (8.5) | 64 (8.1) |
| History of hypertension, n (%) | 871 (28.6) | 203 (27.5) | 226 (29.9) | 212 (27.6) | 230 (29.3) |
Values are means (standard deviation) unless otherwise noted.
MTOPS = The Medical Therapy of Prostatic Symptoms; AUA = American Urological Association; PSA = prostate-specific antigen; BMI = body mass index
Hazard ratios (95% CI) for the treatment arms were as follows: doxazosin 0.54 (0.40–0.72), finasteride 0.60 (0.45–0.80), combination 0.27 (0.19–0.39)